RxDoctor Payments Data

Michael Jones, MD

Family Medicine · Bryan, TXNPI 1407881881

Payments from drug & device makers

$17,955in general payments, 2019–2025

Across 1,040 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • AbbVie$2K
  • Amgen$799
  • Boehringer Ingelheim$758
  • plus $8K from 52 others

What the payments were for

  • Food & beverage$17,73699%
  • Education$2191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk168$2,918
AstraZeneca107$2,224
Lilly USA, LLC75$1,588
AbbVie(2 entities)125$1,526
Amgen55$799
Boehringer Ingelheim41$758
Pfizer49$725
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC51$670
Otsuka America Pharmaceutical, Inc.28$528
Bayer21$453
Teva Pharmaceuticals USA, Inc.29$426
Takeda Pharmaceuticals U.S.A., Inc.29$422
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)20$408
Amarin Pharma, Inc.23$400
GSK16$335
Astellas Pharma US Inc15$317
Lundbeck LLC14$316
Gilead12$258
Merck17$247
Johnson & Johnson11$224
Kowa Pharmaceuticals America, Inc.13$219
Arbor Pharmaceuticals, Inc.15$206
Novartis9$200
Axsome Therapeutics, Inc.7$181
Supernus Pharmaceuticals, Inc.8$148
Biohaven Pharmaceuticals, Inc.8$131
Esperion Therapeutics, Inc.7$126
Exact Sciences6$108
Idorsia Pharmaceuticals US Inc7$104
Eisai Inc.6$89
Mylan Specialty L.p.3$85
Radius Health, Inc.3$54
Stryker1$51
Tolmar, Inc.3$51
Biogen3$50
Zyla Life Sciences, Inc.3$49
Antares Pharma, Inc.3$49
Viatris Specialty LLC2$42
Sumitomo Pharma America, Inc.2$41
Bausch Health US, LLC3$40
Medicure Pharma Inc.1$38
Upsher-smith Laboratories LLC2$32
Sanofi-aventis U.S. LLC2$31
Avanir Pharmaceuticals, Inc.2$28
Aytu Biopharma, Inc.2$27
OWP Pharmaceuticals, Inc.1$26
Verity Pharmaceuticals Inc.1$26
Biohaven Pharmaceutical Holding Company Ltd.1$24
E.r. Squibb & Sons, L.L.C.1$22
Abbott1$21
Genentech USA, Inc.1$20
IBSA Pharma Inc.1$18
Tris Pharma Inc1$17
Shire North American Group Inc1$13
Philips North America LLC1$13
Ironshore Pharmaceuticals Inc.1$12
OVIK Health, LLC1$12
Neuronetics, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,955 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$101,472
Medicare patients
210
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide249$291,217
OzempicSemaglutide227$268,651
FarxigaDapagliflozin Propanediol188$166,790
JardianceEmpagliflozin150$135,267
RexultiBrexpiprazole61$97,185
EliquisApixaban87$85,810
TrulicityDulaglutide53$64,177
Repatha SureclickEvolocumab73$49,520
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$45,454
KerendiaFinerenone56$43,764
TradjentaLinagliptin42$43,569
Dupixent SyringeDupilumab11$40,951
JanuviaSitagliptin Phosphate39$40,459
GemtesaVibegron42$33,213
LinzessLinaclotide32$27,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,588$355,393302 claims
Novo NordiskOzempic, Rybelsus$2,918$291,860252 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,224$188,360224 claims
Boehringer IngelheimJardiance, Tradjenta$758$178,837192 claims
Otsuka America Pharmaceutical, Inc.Rexulti$528$97,18561 claims
PfizerEliquis$725$85,81087 claims
AbbVieLinzess, Vraylar, Synthroid$1,526$56,151133 claims
MerckJanuvia, Janumet$247$53,93454 claims
GSKTrelegy Ellipta$335$45,45450 claims
BayerKerendia$453$43,76456 claims
Sumitomo Pharma America, Inc.Gemtesa$41$33,21342 claims
Johnson & JohnsonXarelto$224$27,19733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →